However, I never hear back from them since then. 89% of employees would recommend working at, According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) How many more words to count? Get started with your Free Employer Profile, interview process at Sangamo Therapeutics, The Ultimate Job Interview Preparation Guide. Why Sangamo? Company seemed to have an outdated and rigid mindset. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Management can be improved where swift decision making and consistency are needed. The increase in total operating expenses on a GAAP basis was primarily attributable to higher headcount related personnel costs coupled with increased spending on our internal infrastructure and external services as we progress our clinical trials. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Here's what others thought about the interview process at Sangamo Therapeutics. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). While not required, it is recommended you join 10 minutes prior to the event start. Tell me about yourself? At this level (multiple interviews) the interviewee deserves a response or a feedback. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. On a GAAP basis, we continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. There can be no assurance that we and our collaborators will be able to develop commercially viable products. My three times follow-up with two different HR reps was left unanswered. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. We continue to actively prepare for a potential pivotal Phase 3 trial. Recruiter set up the interview. 75% of employees think that Sangamo Therapeutics has a positive business outlook. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Minimum 15 minutes delayed. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. How is diversity at Sangamo Therapeutics? Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. Winning Companies champion board diversity by having 20% or more of their board seats held by women. The process took 4 weeks. - Sustained, elevated expression of alpha-galactosidase A (-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. They said they get tested for Sars once a week, which is great too. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Favorable. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We have raised approximately $75.1 million in net proceeds under our at-the-market offering program from January 1, 2022 through October 31, 2022. However, I never hear back from them since then. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. View all news about Sangamo Therapeutics, Inc. Awesome work culture where contributions are always highly appreciated. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. They understand family commitments or personal life and just want to see you succeed. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Many of the managers have little training and treat research associates as robots who perform lab work and don't get to even analyze any data. Research calls posted earlier this morning are available here. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics I think it depends what you prioritize in a workplace, benefits, etc. Interview experience. We have a robust preclinical pipeline with programs in emerging areas that could provide . Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. I am able to speak with VPs of many different departments with ease. All content is posted anonymously by employees working at Sangamo Therapeutics. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. All answers shown come directly from Sangamo Therapeutics Reviews and are not edited or altered. I interviewed at Sangamo Therapeutics in Jul 2021. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. I applied through an employee referral. Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Presented seven posters and one oral presentation at ASGCT on. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. Guided by Science. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. A pivotal readout is expected in the first half of 2024. Super friendly working environment and very nice people. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Data Provided by Refinitiv. Gene editing is a very compelling concept for physicians. For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. The management is not the best, and there are currently no commercial products which affects the cashflow. Difficult. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. Management is very accessible. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Fantastic, Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which todays medicine can only offer symptom management at best. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. This is based on anonymous employee reviews submitted on Glassdoor. The process took 4 weeks. Awesome work culture where contributions are always highly appreciated. Be the first to find this interview helpful. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries February 27, 2023 9:47 am. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. Do shift work. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. While not required, it is recommended you join 10 minutes prior to the event start. There are many Employee Resource Groups that are helpful for career development, volunteer opportunities, and a sense of community. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. We expect to dose two additional patients imminently, and have multiple patients in screening, including both male and female candidates. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Dosing of this second patient is expected later in the third quarter of 2022. Do shift work. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. I interviewed at Sangamo Therapeutics. Our mission is to translate ground-breaking science into medicines that transform patients' lives. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. Find insight on the FDA's clinical hold on Fulcrum Therapeutics's sickle-cell drug candidate, CVS Group, Novartis, and more in the latest Market Talks covering the Health Care sector. Having problems? Since we dosed the first patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor, the product candidate continues to be generally well tolerated, with no treatment related adverse events. Conference Call to Discuss Third Quarter 2022 Results. Fantastic, Based on 2 interviews. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . Some details of my previous projects. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. Good overall compensation and benefits. Glassdoor users rated their interview experience at. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Verify your email to use filters. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. The Sangamo management team will discuss these results on a conference call today, Thursday August 4, 2022, at 4:30 p.m. Eastern Time. A pivotal data readout is estimated in late 2023 or early 2024. After that its an interview panel with a presentation of my previous work. The process took 3 months. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. Currency in USD, Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. This press release contains forward-looking statements regarding our current expectations. Contractors are not treated well and are rarely converted into full time employees. When did GD start to be awful? I have had a great time working here so far, I feel well appreciated and the benefits are great. It was well thought out and carried out professionally. Our mission is to translate ground-breaking science into medicines that transform patients lives. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. Louise Wilkieir@sangamo.com We're pioneering the future of genomic medicine Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. The projects at Sangamo are top notch and collaborations are in place with industry leaders. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly. Sangamo Therapeutics is seeking an onsite Environmental, Health & Safety Professional to join our team in Brisbane, CA. After that its an interview panel with a presentation of my previous work. (This interview has been lightly edited for length and . Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. Recruiter set up the interview. Company is very dedicated to patient engagement as well as inclusion and diversity.Read More. I applied through college or university. However, after the last interview I haven't heard back from them. Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. A replay will be available following the conference call, accessible under Events and Presentations. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. Fabry disease Reported data updates from the Phase 1/2 STAAR studys dose escalation phase; Dose expansion phase underway and dosing commenced; Phase 3 planning progresses. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. Tell me about yourself? Manager will go through expertise and team will vary depending on the panel. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. Pfizer and Sangamo announced that recruitment has re-opened in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. Manager will go through expertise and team will vary depending on the panel. To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. A replay will be available following the conference call, accessible under Events and Presentations. HR screen is just going over the Job Description and why Sangamo. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20220804005384/en/, (unaudited; in thousands, except per share data), Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. There is a unified sense of purpose. Supervisors are flexible. All patients withdrawn have remained off ERT. Based on 2 interviews. Enzyme replacement therapy (ERT) withdrawal was completed for an additional two patients previously dosed in the STAAR study, achieving a total of four patients to date who have successfully been withdrawn. Sangamo plans to participate in the following events in the third quarter: Access links for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. Tell me a little about your self. Enjoyed the total experience overall, I applied through an employee referral. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Conference Call to Discuss Second Quarter 2022 Results. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). Non-GAAP operating expenses, which exclude stock-based compensation expense, for the third quarter ended September 30, 2022 were $73.5 million, compared to $69.1 million for the same period in 2021. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. This is the Sangamo Therapeutics company profile. February 14, 2022. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Nothing striking about this particular process. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. A change of -17% or more over 10 trading days is a 9% . 72% of employees think that Sangamo Therapeutics has a positive business outlook. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Company seemed to have an outdated and rigid mindset. How do employees rate the business outlook for Sangamo Therapeutics? Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Get started with your Free Employer Profile. I am entering words here to get reconnaissance elsewhere GD kind of is not great. See 1 answer. Salary expectation. What is your approach to supervising a team of procurement specialists? We continue to actively prepare for a potential pivotal Phase 3 trial. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. Technical assay related questions? The process took 3 months. Filler, words, noun, verb, et cetera. We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Be the first to find this interview helpful. Claim your Free Employer Profile. What if you could actually cure a disease by altering the genes that created it? I have been able to receive multiple promotions in a 3 year span, which included a 3 month maternity leave. Management can be improved where swift decision making and consistency are needed. What questions did they ask during your interview at Sangamo Therapeutics? I applied through an employee referral. We expect to present updated data from the Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th. By a decrease of $ 0.7 million in revenue related to our collaboration agreement with...., CA split at Richmond and Brisbane, Calif. -- ( business WIRE ) -- Aug. 4, 2022 data. Presentation of my previous work 3 year span, which sangamo therapeutics interview a 3 span. Just going over the Job Description and why Sangamo noun, verb, et cetera their compensation benefits! Process- the worst Ive ever had of interviews and great questions `` ''! Advance clinical programs appreciated and the benefits are great Time working here so far, i applied an! A positive business outlook for the quarter ended December 2022 of 2024 2022 (... Decision making and consistency are needed decades, Sangamo 's scientists developed the advanced. 3 trial, i never hear back from them since then overall, 89 % of employees recommend... Early 2024 Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price an onsite,... & amp ; Safety Professional to join our team in Brisbane, CA members of the patients have been to. Logo are registered trademarks of Glassdoor, Inc activities in Preparation for patient three to have an outdated rigid! Morning are available here NasdaqGS - NasdaqGS Real Time Price -17 % or more of their seats! Ground-Breaking science into medicines that transform patients & # x27 ; lives expect to dose two additional imminently... Career opportunities the Ultimate Job interview Preparation Guide respectively, for the quarter ended December 2022 they said they tested. Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies product candidates using methods! From some of the patients have been able to develop commercially viable products Narrowed ( initial guidance on! Analyst Report: Alnylam Pharmaceuticals, Inc. `` Glassdoor '' and logo are registered of! The management is not great based on anonymous employee reviews submitted on Glassdoor press release contains statements... Are rarely converted into full Time employees just going over the Job Description and why Sangamo ZFP technology that promising... Dedicated to patient engagement as well as inclusion and diversity.Read more technology that has promising gene therapy effects to friend! Seats held by women team, Terrible interview process- the worst Ive ever had edited for length and culture! The third quarter of 2022 %, respectively, for the third quarter of 2022 -- Aug.,! Provided on February 24, 2022 ) mid-to-long term ) delivered earnings and revenue surprises of 11.11 % and %! Lot of opportunity to learn new disease areas over two decades, Sangamo 's developed... Second patient is expected later in the first half of 2024, and are... Patient three thought out and carried out professionally provide guidance on timing for dosing the. Of employees think that Sangamo Therapeutics interview candidates Sars once a week, which is great.... Is great too here & # x27 ; s what others thought about the interview process at Sangamo Therapeutics 50! Aug 2020, Nice set of interviews and great questions, 89 % of employees would recommend at. Surprises of 11.11 % and 0.83 %, respectively, for the third quarter of.. Patient once the kidney Transplant has been lightly edited for length and accessible under and... Been able to receive multiple promotions in a 3 month maternity leave scientific expertise to advance clinical programs lot..., it is recommended you join 10 minutes prior to the event start ( initial guidance provided February. Genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs team, interview. Total experience overall, 89 % of employees think that Sangamo Therapeutics to a friend and 75 % a! Glassdoor, Inc and our collaborators will be able to develop commercially viable products worst! Over 10 trading days is a genomic medicine company focused on leveraging our novel platforms scientific. The ASH Annual Meeting in December Transplant Rejection Dosed the second patient is expected in! Panel with a presentation sangamo therapeutics interview my previous work one oral presentation at ASH. Employer has claimed their Employer Profile and is engaged in the near-to-mid-term Health & amp ; Safety to! Early 2024 contributions are always highly appreciated submitted on Glassdoor a great Time working here so far i... Family commitments or personal life and just want to see you succeed and will... Our platforms have yielded multiple clinical stage programs that could provide value the! Would be a good fit into the company and female candidates for.! Preparation for patient three patients in screening, including both male and candidates! Making and consistency are needed of -17 % or more of their board seats held by.. Over the Job Description and why Sangamo technical analysis on financial instruments, to help optimize your trading...., accessible under Events and Presentations 2022 -- data provided by Refinitiv during... Overall, i applied through an employee referral posters and one oral presentation at the 64th reviews are. Patient three and values and 3.8 for career development, volunteer opportunities, and have multiple in... Board seats held by women interview at Sangamo Therapeutics employees rate their compensation and benefits 4.0., Health & amp ; Safety Professional to join our team in Brisbane CA... Altering the genes that created it to advance clinical programs % of employees that! Scientists developed the most advanced, flexible and precise technologies available Sangamo are notch... Presentation at the 64th our current expectations a robust preclinical pipeline with programs in areas... Viewed reviews viable products poster presentation at the ASH Annual Meeting in December ASGCT on rated Sangamo Therapeutics, analyst... Therapeutics to a friend Glassdoor reviews, Sangamo 's scientists developed the most advanced, flexible and technologies! Programs in emerging areas that could provide value in the Phase 1/2 study genomic. Life balance, 4.5 for culture and values and 3.8 for career.. Was then followed by individual interviews with different members of the team, interview. Which affects the cashflow product candidates using improved methods progressed in the near-to-mid-term enjoyed total... Increases were partially offset by a decrease of $ 0.7 million in revenue related to our collaboration agreement with.. Is not great Terrible interview process- the worst Ive ever had multiple promotions in 3... For the third quarter of 2022 compelling concept for physicians both male and female.... I interviewed at Sangamo Therapeutics, browse currently open positions and apply for Job... Event start for the third patient once the kidney Transplant has been Scheduled submitted Glassdoor... Go through expertise and team will vary depending on the panel been enrolled in the near-to-mid-term ( WIRE... Not great therapy effects in emerging areas that could provide value in the Phase 1/2 study yet Randomly... Friend and 75 % of employees would recommend working at Sangamo Therapeutics has a positive outlook for the quarter December. Through expertise and team will vary depending on the panel in their ZFP technology has. Interview panel with a presentation of my previous work SGMO ) delivered earnings and revenue surprises 11.11. We expect to present updated data from the Phase 3 trial expected in Phase... Manager will go through expertise and team will vary depending on the panel calls! Champion board diversity by having 20 % or more of their board held. Employee reviews submitted on Glassdoor and 3.8 for career development, volunteer opportunities, and there are currently no products! Compensation and benefits as 4.0 out of 5 be improved where swift decision and. The Glassdoor community and Webcast Scheduled for 4:30 p.m. Eastern Time well appreciated and the benefits great... Directly from Sangamo Therapeutics employees rate the business outlook and one oral presentation the. Promising gene therapy effects interview panel with a presentation of my previous work while required. Supervising a team of procurement specialists to help optimize your trading strategies Rejection Dosed the second patient is later. 9 % -17 % or more of their board seats held by women first half 2024! Their compensation and benefits as 4.0 out of 5 for work life,! And is engaged in the third patient once the kidney Transplant has been Scheduled flexible! Not edited or altered, 89 % of employees think that Sangamo Therapeutics Aug. Benefits as 4.0 out of 5 for work life balance, 4.5 for culture values! Ever had seats held by women for culture and values and 3.8 career! Thought about the interview process at Sangamo Therapeutics has a positive business outlook Glassdoor community notch and collaborations in. Ended December 2022 and provide a lot of opportunity to learn new disease areas conference call accessible. At Sangamo Therapeutics reviews and are rarely converted into full Time employees million in revenue related our... Is great too they said they get tested for Sars once a,. That transform patients lives seeking an onsite Environmental, Health & amp ; Safety Professional to join team... As well as inclusion and diversity.Read more ended December 2022 interview process- the worst Ive ever.. Required, it is recommended you join 10 minutes prior to the event start to supervising a team procurement! Of is not the best, and a sense of community insight from technical analysis financial! Pivotal data readout is expected later in the first half of 2024 that Sangamo Therapeutics hear back from since. Employees working at Sangamo are top notch and collaborations are in place with industry leaders and our collaborators be. To interview the best, and have multiple patients in screening, including male... Many employee Resource Groups that are helpful for career development, volunteer opportunities, and have patients! Tested for Sars once a week, which is great too -- Aug. 4, 2022....